Vancomycin for Infusion

Details for the public consultation of this monograph are as follows:

<table>
<thead>
<tr>
<th>EAG ABS</th>
<th>Antibiotics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contact Details</strong></td>
<td><a href="mailto:peter.crowley@mhra.gov.uk">peter.crowley@mhra.gov.uk</a></td>
</tr>
<tr>
<td></td>
<td><a href="mailto:amelia.thomson@mhra.gov.uk">amelia.thomson@mhra.gov.uk</a></td>
</tr>
<tr>
<td><strong>Deadline for Comment</strong></td>
<td>31st December 2021</td>
</tr>
<tr>
<td><strong>Target Publication (subject to change)</strong></td>
<td>BP 2023</td>
</tr>
<tr>
<td><strong>Notes:</strong></td>
<td><strong>Revised Monograph</strong></td>
</tr>
<tr>
<td></td>
<td>If limits are too restrictive, please provide batch/stability data to demonstrate that an increase is required.</td>
</tr>
<tr>
<td></td>
<td><strong>Definition:</strong> Monograph title corrected.</td>
</tr>
<tr>
<td></td>
<td><strong>Acidity, Clarity of solution, Water:</strong> Tests removed.</td>
</tr>
<tr>
<td></td>
<td><strong>Related substances and Vancomycin B:</strong> Technical corrections.</td>
</tr>
<tr>
<td></td>
<td><strong>Impurities:</strong> New section added.</td>
</tr>
</tbody>
</table>

**Action and use**

Glycopeptide antibacterial.

**DEFINITION**

Vancomycin for Infusion is a sterile material consisting of Vancomycin Hydrochloride with or without excipients. It is supplied in a sealed container.

*The contents of the sealed container comply with the requirements for Powders for Injections or Infusions stated under Parenteral Preparations and with the following requirements.*

**IDENTIFICATION**

A. In the test for Related substances and Vancomycin B, record the UV spectrum of the principal peak in the chromatograms obtained with solutions (1) and (2) with a diode array detector in the range of 210 to 400 nm:

the UV spectrum of the principal peak in the chromatogram obtained with solution (1) is similar to that of the peak in the chromatogram obtained with solution (2);

the retention time of the principal peak in the chromatogram obtained with solution (1) is similar to that of the peak in the chromatogram obtained with solution (2).

B. Yield reaction A characteristic of chlorides, Appendix VI.
Related substances and Vancomycin B

Carry out the method for liquid chromatography, Appendix III D, using the following solutions and the normalisation procedure.

1. Dissolve a quantity of the powder containing 0.1 g of Vancomycin Hydrochloride with 20 mL of water and dilute to 25 mL.
2. 0.4% w/v of vancomycin for system suitability EPCRS.
3. Expose 4 mg of vancomycin for system suitability EPCRS to 80-100% relative humidity at 42 ± 2° for at least 7 days. Allow to cool. Add 1 mL of water and dissolve the sample with the aid of ultrasound (in situ generation of impurities B, D, E, G, and L).
4. Dilute 1 volume of solution (2) to 100 volumes with 0.1% v/v acetic acid. Dilute 1 volume of this solution to 10 volumes with the same solvent.

CHROMATOGRAPHIC CONDITIONS

(a) Use a stainless steel column (15 cm × 2.1 mm) packed with end-capped, charged-surface, ethylene-bridged, octadecylsilyl silica gel for chromatography (hybrid material) (1.7 µm) (Acquity CSH C18 is suitable).
(b) Use gradient elution and the mobile phase described below.
(c) Use a flow rate of 0.3 mL per minute.
(d) Use a column temperature of 40°.
(e) Use a detection wavelength of 280 nm.
(f) Use an autosampler temperature of 5°.
(g) Inject 20 µL of each solution.

MOBILE PHASE

Mobile phase A 3 volumes of acetonitrile, 4 volumes of methanol and 93 volumes of a 0.7% w/v solution of tris(hydroxymethyl)aminomethane previously adjusted to pH 8.1 with a 20% v/v solution of glacial acetic acid.

Mobile phase B 10 volumes of acetonitrile, 40 volumes of methanol and 50 volumes of a 0.7% w/v solution of tris(hydroxymethyl)aminomethane previously adjusted to pH 8.1 with a 20% v/v solution of glacial acetic acid.

<table>
<thead>
<tr>
<th>Time (Minutes)</th>
<th>Mobile phase A (% v/v)</th>
<th>Mobile phase B (% v/v)</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-7</td>
<td>88</td>
<td>12</td>
<td>isocratic</td>
</tr>
<tr>
<td>7-21</td>
<td>88→75</td>
<td>12→25</td>
<td>linear gradient</td>
</tr>
<tr>
<td>21-35</td>
<td>75→25</td>
<td>25→75</td>
<td>linear gradient</td>
</tr>
<tr>
<td>35-37</td>
<td>25</td>
<td>75</td>
<td>isocratic</td>
</tr>
<tr>
<td>37-38</td>
<td>25→88</td>
<td>75→12</td>
<td>linear gradient</td>
</tr>
<tr>
<td>38-45</td>
<td>88</td>
<td>12</td>
<td>re-equilibration</td>
</tr>
</tbody>
</table>

When the chromatograms are recorded under the prescribed conditions the retention times relative to vancomycin B (retention time, about 19 minutes) are: impurity E, about 0.37; impurity L, about 0.66; impurity B, about 0.70; impurity A, about 0.76; impurity F, about 0.82; impurity G, about 0.90; impurity H, about 0.94; impurity M, about 1.11; impurity I, about 1.14; impurity J, about 1.20; impurity D, about 1.24; impurity K, about 1.50 and impurity C, about 1.86.
The test is not valid unless, in the chromatogram obtained with solution (3):

the *resolution* between the peaks due to impurity L and impurity B is between 1.5 to 5.0;

the *resolution* between the peaks due to impurity G and impurity H is between 1.5 to 4.0.

If the resolution between the peaks due to impurities L and B is greater than 5.0, adjust the pH of solution A to a lower value. If the resolution between the peaks due to impurities G and H is greater than 4.0, adjust the pH of solution A to a higher value.

**LIMITS**

Identify any peaks in the chromatogram obtained with solution (1) corresponding to vancomycin impurities A, C, F, H, I, J, K and M using the chromatogram obtained with solution (2) and any peaks corresponding to vancomycin impurities B, D, E, G, and L using the chromatogram obtained with solution (3).

In the chromatogram obtained with solution (1), integrate all peaks present with an area greater than the area of the principal peak in the chromatogram obtained with solution (4) to determine the total peak area. Calculate the percentage content of each of the components and impurities by *normalisation*:

the content of Vancomycin B is not less than 91.0%;

the area of any peaks due to impurities A or H are not greater than 3.0%;

the sum of the areas of any peaks due to impurities B and E is not greater than 2.0%;

the area of any peak due to impurity J is not greater than 1.6%;

the area of any peaks due to impurities D, F or M are not greater than 1.5%;

the area of any peaks due to impurities G, I or K are not greater than 1.2%;

the area of any peak due to impurity C is not greater than 1.0%;

the area of any other *secondary peak* is not greater than 0.8%;

the sum of the areas of all the *secondary peaks* is not greater than 9.0%.

**Bacterial endotoxins**

Carry out the *test for bacterial endotoxins, Appendix XIV C*. Dissolve the contents of the sealed container in *tris-chloride buffer pH 7.4* prepared using *water BET* to give a solution containing 9000 IU of vancomycin per mL (solution A). The endotoxin limit concentration of solution A is 2.5 IU of endotoxin per mL.

**ASSAY**

Determine the weight of the contents of 10 containers as described in the test for *uniformity of weight, Appendix XII C1, Powders for Parenteral Administration*.

Mix the contents of the 10 containers and carry out the *microbiological assay of antibiotics, Appendix XIV A*. The precision of the assay is such that the fiducial limits of error are not less than 95% and not more than 105% of the estimated potency.
For a container of average content weight, the upper fiducial limit of error is not less than 95.0% and the lower fiducial limit of error is not more than 115.0% of the stated number of IU.

LABELLING

The label of the sealed container states (1) the total number of IU (Units) contained in it and (2) the number of IU (Units) per mg.

IMPURITIES

The impurities limited by the requirements of this monograph include those listed under Vancomycin Hydrochloride.